Abstract:The JAK-STAT signalling pathway is primarily involved in cytokine signalling and induces various factors namely, erythropoietin, thrombopoietin, interferons, interleukins, and granulocyte colony-stimulating factors. These factors tremendously influenced understanding human health and illness, specifically cancer. Inhibiting the JAK/STAT pathway offers enormous therapeutic promises against cancer. Many JAK inhibitors are now being studied due to their efficacy in various cancer treatments. Further, the Nitrogen-heterocyclic (N-heterocyclic) scaffold has always shown to be a powerful tool for designing and discovering synthetic compounds with diverse pharmacological characteristics. The review focuses on several FDA-approved JAK inhibitors and their systematic categorization. The medicinal chemistry perspective is highlighted and classified review on the basis of N-heterocyclic molecules. Several examples of designing strategies of N-heterocyclic rings including pyrrolo-azepine, purine, 1H-pyrazolo[3,4-d]pyrimidine, 1H-pyrrolo[2,3-b]pyridine, pyrazole, thieno[3,2-d] pyrimidine, and, pyrimidine-based derivatives and their structure-activity relationships (SAR) are discussed. Among the various N-heterocyclic-based JAK inhibitors pyrimidine-containing compound 1 exhibited excellent inhibition activity against JAK2WT and mutated-JAK2V617F with IC50 of 2.01 and 18.84 nM respectively. Amino pyrimidine-containing compound 6 and thiopheno[3,2-d]pyrimidine-containing compound 13 expressed admirable JAK3 inhibition activity with IC50 of 1.7 nM and 1.38 nM respectively. Our review will support the medicinal chemists in refining and directing the development of novel N-heterocyclic-based JAK inhibitors.

Current Application Status and Structure-Activity Relationship of Selective and Non-Selective JAK Inhibitors in Diseases

Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors

Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors

A Comprehensive Overview of Globally Approved JAK Inhibitors

Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship

JAK inhibitor selectivity: new opportunities, better drugs?

Synthesis and clinical application of small-molecule inhibitors of Janus kinase

JAK Inhibitors: Prospects in Connective Tissue Diseases

Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis

Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors

Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018)

JAK inhibitors in 2019, synthetic review in 10 points

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity

Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

[JAK inhibition in the treatment of inflammatory rheumatic diseases]

Tyrosine Kinase 2 Inhibitors: Synthesis and Applications in the Treatment of Autoimmune Diseases

Prospects of Janus Kinase Inhibitors in the Treatment of Skin Diseases

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story

Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure-activity relationship